Skip to main content
TipRanks
Go Ultimate75% OFF

CombiGene AB (LARK) AI Stock Analysis

0 Followers
SE:LARK

CombiGene AB

(Nasdaq OMX AB:LARK)

Select Model
Rating:50Neutral
Price Target:SEK 2.00â–¼(-13.42% Downside)
Action:reiterated
Date:09/06/26

Overall score is held back primarily by weak financial performance quality: negative operating profitability and continued cash burn outweigh the benefit of a debt-free, well-capitalized balance sheet. Technicals are neutral-to-slightly weak with the stock below key moving averages. Valuation is mixed, with a high P/E limiting attractiveness despite an unusually high dividend yield.

Positive Factors
Debt-Free Balance SheetA debt-free structure and substantial equity base reduce financial risk and provide resilience while the company advances its programs. This capital position can preserve strategic flexibility and limit financing pressure during continued research and development investment.
Negative Factors
Persistent Cash BurnPersistent negative operating and free cash flow means the business is not yet self-funding its activities. Continued cash consumption can require additional capital or transactions to sustain development, reducing flexibility even though the balance sheet currently carries no debt.

CombiGene AB (LARK) vs. iShares MSCI Sweden ETF (EWD)

-20%-10%0%10%20%30%SE:LARK+1.32%EWD+15.85%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 45.74M
Dividend Yield
86.58%
Average Volume (3M)
7,326
Price to Earnings (P/E)
39.2
Beta (1Y)
0.02
Revenue Growth
―
EPS Growth
―
Country
Sweden
Employees
1
Sector
Financial
Sector Strength
68
Industry
Asset Management

CombiGene AB Business Overview & Revenue Model

Company Description

Lärkberget AB (publ) functions as an investment firm, engaging in a variety of financial endeavors. Its operations encompass direct capital deployment into low-risk instruments, broader financial investments, acquiring stakes in privately held yet pr...

CombiGene AB Financial Statement Overview

Summary

Balance sheet strength (zero debt and substantial equity) supports resilience, but operating fundamentals remain weak. Despite TTM net income turning positive and revenue rebounding, gross and operating profit are still negative and cash flow remains meaningfully negative, indicating the turnaround is not yet self-funding or sustainably profitable.

Income Statement

28Negative

Balance Sheet

74Positive

Cash Flow

24Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue642.00K0326.00K5.54M26.70M84.04M
Gross Profit-2.14M-8.16M-46.78M-21.29M-19.20M15.16M
EBITDA2.72M-7.19M-43.15M-35.98M-5.86M23.56M
Net Income1.20M-12.36M-44.88M-35.66M-6.16M20.96M
Balance Sheet
Total Assets57.56M56.73M75.88M120.61M158.22M166.22M
Cash, Cash Equivalents and Short-Term Investments6.17M5.84M73.75M101.44M131.78M136.74M
Total Debt000000
Total Liabilities846.00K1.24M4.30M4.16M6.10M7.94M
Stockholders Equity56.71M55.49M71.58M116.46M152.12M158.28M
Cash Flow
Free Cash Flow-2.57M-12.78M-29.95M-30.67M-16.67M21.97M
Operating Cash Flow-2.57M-12.78M-29.95M-30.56M-16.67M22.11M
Investing Cash Flow-49.97M-49.78M-81.00K-988.90K0-147.73K
Financing Cash Flow0-3.96M00065.88M

CombiGene AB Technical Analysis

Technical Analysis SentimentPositive
Last Price2.31

Price Trends

50DMA2.28Positive
100DMA2.26Positive
200DMA2.24Positive

Market Momentum

MACD0.01Negative
RSI51.37Neutral
STOCH58.17Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:LARK, the sentiment is Positive. The current price of 2.31 is above the 20-day moving average (MA) of 2.30, above the 50-day MA of 2.28, and above the 200-day MA of 2.24, indicating a bullish trend. The MACD of 0.01 indicates Negative momentum. The RSI at 51.37 is Neutral, neither overbought nor oversold. The STOCH value of 58.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:LARK.

CombiGene AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (68)

Financial Indicators

SE:LARK against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *68Neutral$18.00B11.429.92%3.81%9.73%1.22%
SE:EQTSE:EQT59NeutralSEK 392.35B32.50―1.48%-18.18%20.49%
SE:LARKSE:LARK50NeutralSEK 45.74M39.152.14%86.58%――
SE:ATINSE:ATIN43NeutralSEK 289.46M-5.32――-33.93%-9.82%

* Financial Sector Average

Performance Comparison

-20%0%20%SE:LARKSE:ATINSE:EQTDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:LARK and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:LARKCombiGene AB2.310.031.32%
SE:ATINAthanase Innovation AB15.00-1.80-10.71%
SE:EQTEQT AB314.001.160.37%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 06, 2026